JP2023507569A5 - - Google Patents

Info

Publication number
JP2023507569A5
JP2023507569A5 JP2022537497A JP2022537497A JP2023507569A5 JP 2023507569 A5 JP2023507569 A5 JP 2023507569A5 JP 2022537497 A JP2022537497 A JP 2022537497A JP 2022537497 A JP2022537497 A JP 2022537497A JP 2023507569 A5 JP2023507569 A5 JP 2023507569A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
composition according
alkyl
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507569A (ja
JP7737721B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066182 external-priority patent/WO2021127543A1/en
Publication of JP2023507569A publication Critical patent/JP2023507569A/ja
Publication of JP2023507569A5 publication Critical patent/JP2023507569A5/ja
Priority to JP2025075567A priority Critical patent/JP2025107315A/ja
Application granted granted Critical
Publication of JP7737721B2 publication Critical patent/JP7737721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537497A 2019-12-19 2020-12-18 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 Active JP7737721B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025075567A JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950886P 2019-12-19 2019-12-19
US62/950,886 2019-12-19
PCT/US2020/066182 WO2021127543A1 (en) 2019-12-19 2020-12-18 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025075567A Division JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Publications (3)

Publication Number Publication Date
JP2023507569A JP2023507569A (ja) 2023-02-24
JP2023507569A5 true JP2023507569A5 (cg-RX-API-DMAC7.html) 2023-12-21
JP7737721B2 JP7737721B2 (ja) 2025-09-11

Family

ID=76478828

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537497A Active JP7737721B2 (ja) 2019-12-19 2020-12-18 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP2025075567A Pending JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025075567A Pending JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Country Status (8)

Country Link
US (1) US20230098667A1 (cg-RX-API-DMAC7.html)
EP (1) EP4077333A4 (cg-RX-API-DMAC7.html)
JP (2) JP7737721B2 (cg-RX-API-DMAC7.html)
CN (1) CN115175911A (cg-RX-API-DMAC7.html)
AU (1) AU2020405233A1 (cg-RX-API-DMAC7.html)
IL (1) IL294031A (cg-RX-API-DMAC7.html)
MX (1) MX2022007725A (cg-RX-API-DMAC7.html)
WO (1) WO2021127543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12039851B2 (en) * 2019-05-23 2024-07-16 Lifeguard Ai, Inc. System and a method for surveilling swimmers
WO2024023268A1 (en) 2022-07-29 2024-02-01 F. Hoffmann-La Roche Ag Characterisation of neurological dysfunction
EP4572852A1 (en) * 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032889B1 (en) * 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3310785B1 (en) * 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4178961A4 (en) * 2020-07-10 2024-07-31 Agenebio, Inc. POLYMORPHS OF A GABAA APLHA5 AGONIST AND METHODS OF USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT
JP7867287B2 (ja) * 2020-07-10 2026-05-29 エージンバイオ, インコーポレイテッド Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法

Similar Documents

Publication Publication Date Title
US20250340558A1 (en) Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
JP2021528427A5 (cg-RX-API-DMAC7.html)
KR100737090B1 (ko) 축합 이미다졸륨 유도체
AU2015335783B2 (en) Tricyclic atropisomer compounds
JP2017500334A5 (cg-RX-API-DMAC7.html)
WO2000075113A1 (en) Novel heterocyclic carboxamide derivatives
JP2016128414A (ja) ピリミジン誘導体の製造プロセス
CN116194459A (zh) 抗血小板药物和其用途
CN105228620A (zh) 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
JP2018521034A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
AU2021273001A1 (en) ENPP1 modulators and uses thereof
JP2023509944A5 (cg-RX-API-DMAC7.html)
JP2019504090A (ja) ダサチニブの固体状態形態およびそれらの調製プロセス
JP2022510587A5 (cg-RX-API-DMAC7.html)
MX2025006404A (es) Compuestos de pirrolil-sulfonamida fusionados
JP2023534189A5 (cg-RX-API-DMAC7.html)
CN114805352A (zh) 作为pi3k/mtor抑制剂的吡咯并吡啶取代的稠合喹啉化合物
JP2016539994A (ja) α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
JP2022515549A (ja) パントテンアミドアナログ
WO2017040879A1 (en) Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
JP2001512491A (ja) 1−(イソキノリン−1−イル)−4−(1−フェニメチル)ピペラジン;ドーパミン受容体サブタイプ特異的リガンド
WO2010102513A1 (zh) 高哌嗪乙酰肼类衍生物及其制备方法和用途